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Abstract
Background Cancer cachexia is the progressive loss of
skeletal muscle protein that contributes significantly to
cancer morbidity and mortality. Evidence of antioxidant
attenuation and the presence of oxidised proteins in patients
with cancer cachexia indicate a role for oxidative stress.
The level of oxidative stress in tissues is determined by an
imbalance between reactive oxygen species production and
antioxidant activity. This study aimed to investigate the
superoxide generating NADPH oxidase (NOX) enzyme and
antioxidant enzyme systems in murine adenocarcinoma
tumour-bearing cachectic mice.
Methods Superoxide levels, mRNA levels of NOX enzyme
subunits and the antioxidant enzymes superoxide dismutase
(SOD), glutathione peroxidise (GPx) and catalase was
measured in the skeletal muscle of mice with cancer and
cancer cachexia. Protein expression levels of NOX enzyme
subunits and antioxidant enzyme activity was also mea-
sured in the same muscle samples.
Results Superoxide levels increased 1.4-fold in the muscle
of mice with cancer cachexia, and this was associated with
a decrease in mRNA of NOX enzyme subunits, NOX2,
p40phox and p67phox along with the antioxidant enzymes
SOD1, SOD2 and GPx. Cancer cachexia was also
associated with a 1.3-fold decrease in SOD1 and 2.0-fold
decrease in GPx enzyme activity.
Conclusion Despite increased superoxide levels in cachectic
skeletal muscle, NOX enzyme subunits, NOX2, p40phox and
p67phox, were downregulated along with the expression and
activity of the antioxidant enzymes. Therefore, the increased
superoxide levels in cachectic skeletal muscle may be
attributed to the reduction in the activity of endogenous
antioxidant enzymes.
Keywords Cancer cachexia . NADPH oxidase . ROS . O2
− .
Antioxidant . SOD
1 Introduction
Cancer cachexia is a condition of progressive muscle
wasting that develops as a secondary condition in response
to tumour growth [1]. While cachexia develops in a wide
range of pathologies including anorexia nervosa, acquired
immunodeficiency syndrome, amyotrophic lateral sclerosis,
congestive heart failure and various malignant cancers,
cancer cachexia has been reported to develop at a faster rate
than any other cachectic condition [1]. Approximately half
of all patients with cancer experience cachexia and almost a
third of mortalities are estimated to result from cachexia [2].
Tumour growth induces a specific catabolic response in
skeletal muscle that causes the accelerated loss of protein,
characterised by the significant loss of body weight [3].
Animal tumour models have been used to investigate
cancer cachexia, developing up to 30% loss in body weight
after tumour cell implantation. NMRI mice implanted with
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murine adenocarcinoma (MAC) 16 present with solid
tumour growth and cachexia [4], as have been shown in
rats bearing the Yoshida AH-130 hepatoma [5], character-
istic of the human cancer cachectic condition.
An abundance of evidence exists for the induction of the
ubiquitin (Ub)-proteasome proteolytic pathway in the
development of cancer cachexia; however, evidence of
protein oxidation in cancer cachectic patients suggests the
involvement of reactive oxygen species (ROS) [6]. Studies
in both humans and animals with cancer cachexia have
shown the presence of oxidised proteins [6]. Furthermore,
cancer patients have been shown to present with elevated
levels of serum ROS and lower antioxidant levels [7],
indicative of a pro-oxidative shift. Similarly, increased
levels of ROS have been shown in cachectic tumour-
bearing rats, with no compensatory response from antioxidant
enzymes [5]. Although the catabolic mechanism leading to
the severe muscle wasting associated with cancer develop-
ment remains relatively unknown, there is evidence to
suggest a role for ROS [7].
Nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX) is a multicomponent enzyme that when
activated catalyzes the production of superoxide anion
(O2
−). The NOX2 enzyme consists of five subunits
segregated into membrane bound, NOX2 (gp91phox) and
p22phox, and cytosolic, p67phox, p47phox and p40phox, units.
On stimulation, the protein components of the NOX2
enzyme assemble, forming the active oxidase and the
production of O2
− [8]. It has been apparent in recent years
that non-phagocytes possess homologues to NOX2, and
that these NOX enzymes may activate in a similar manner
to the well-established phagocyte NOX2 enzyme [9].
Currently, there are five known NOX homologues
(NOX1-5) found to function in a variety of tissues, with
the expression of both NOX2 and NOX4 enzyme subunits
in skeletal muscle tissue, although its function in this
particular cell system remains undefined [10]. Despite the
unknown functionality of the NOX enzymes in skeletal
muscle tissue, O2
− generated from NOX has been impli-
cated in progressive skeletal muscle damage [11]. The
abundance of evidence for NOX enzyme-generated O2
− in
disease [11], establishes its potential role in the catabolic
skeletal muscle wasting in cancer cachexia.
It is well-known that ROS are generated in skeletal
muscle as an essential by-product of cellular metabolism
and oxidative enzymes [12]. Due to the high metabolic
activity and oxidative capacity of skeletal muscle, the
antioxidant system is a crucial component for the mainte-
nance of cellular oxidative homeostasis [13]. With the
knowledge that ROS are likely catabolic factors in the
development of cancer cachexia, antioxidant enzymes are
of equal importance for their crucial role in the maintenance
of cellular oxidative homeostasis and the protection against
harmful ROS [13]. O2
− is dismutated by the O2
− specific
antioxidant enzyme, superoxide dismutase (SOD). Three
distinct forms of SOD exist in the intracellular cytoplasmic
compartment (SOD1), mitochondria (SOD2) and extracel-
lular matrix (SOD3) [14]. The SOD enzymes catalyse the
conversion of O2
− to H2O2, which is further converted by
catalase and glutathione peroxidise (GPx) scavenging [14].
A depression in these antioxidant enzyme systems can
consequently lead to an imbalance in cellular oxidation and
oxidative tissue damage [13], which has been shown
particularly in response to disease [5]. Endogenous anti-
oxidants such as SOD and GPx are low in cancer patients
presenting with high levels of ROS, indicating the importance
of tight regulation from endogenous antioxidants [7].
The Ub-proteasome proteolytic pathway has been
established in cancer-induced cachexia. In addition,
tumour-derived factors such as TNF-α and proteolysis-
inducing factor (PIF) are well recognised in the cancer
cachectic condition [15]. What is yet to be elucidated,
however, are the downstream mediators of this complex
system, in response to tumour growth and development of
cancer cachexia. A study by Russell et al. [16] proposed a
cachectic pathway of increased Ub gene expression,
downstream of NOX-generated ROS production, estab-
lishing a potential role for the NOX enzymes in mediating
skeletal muscle atrophy through the Ub-proteasome
proteolytic pathway.
Therefore, this study aims to investigate the O2
−
generating NOX and antioxidant enzyme systems in a
well-established animal model of cancer cachexia. In
particular, this study aims to determine O2
− levels and
NOX enzyme system expression (NOX2, NOX4, p22phox,
p40phox, p47phox, p67phox and Rac1) in the skeletal muscle
of cachectic (MAC16) tumour-bearing mice compared to
non-cachectic (MAC13) tumour-bearing mice. Further-
more, this study aims to determine levels of the primary
antioxidants for O2
− and H2O2 dismutation (SOD1, SOD2,
SOD3, catalase and GPx), in the skeletal muscle of tumour-
bearing cachectic mice (MAC16) compared to tumour-
bearing non-cachectic (MAC13) mice.
2 Methods
2.1 Animal model of cancer-induced cachexia
All experimental procedures were carried out with approval
from the Victoria University Animal Ethics Committee
(AEETH 07/05). Two weight-matched groups of female
BALB/c nu/nu mice were maintained under controlled
environmental conditions, 12-h light/dark cycle, 21°C±
2°C, 30% humidity, in conventional cages with ad
libitum access to standard chow and water throughout
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the course of the study. As has previously been
described [4], donor mice were used to establish and
maintain a tumour line, which consistently produced
tumour growth (MAC13) (n=3) and tumour growth with
cachexia (MAC16) (n=4). Tumour fragments grown and
maintained in donor mice were dissected and re-implanted
subcutaneously into the flank of recipient mice with
frequent monitoring and recording of body weight and
tumour size. With cachectic weight loss evident at
approximately 9–12 days post implantation, mice were
anaesthetised, using pentobarbital sodium (70 mg/kg), for
tissue collection before weight loss exceeded 25% of
original body weight or before tumour growth exceeded
1,000 mm3. Skeletal muscle tissue was collected, weighed
and immediately snap-frozen in liquid nitrogen and stored
at −80°C for later use.
2.2 Detection of O2
− by DHE fluorescence staining
Skeletal muscle O2
− was measured using O2
−-sensitive
Dihydroethidium (DHE) dye. Cell-permeable DHE reacts
with O2
−, converting DHE into ethidium fluorescence.
DHE (5 μM) was applied to quadriceps cross-sections
(5 μm) and incubated in a light-protected oven at 37°C for
30°min. The sections were washed with PBS to remove
excess DHE, and fluorescence was assessed by way of
fluorescence microscopy (Axiocam HBO 50/AC, Zeiss,
Germany). The muscle was analysed in three sections to
obtain measurements from the whole tissue. Ethidium
fluorescence density was detected from the whole section
with MCID imaging software (Imaging Research Inc,
Australia) and expressed as arbitrary units of fluorescence.
2.3 Reverse transcription real-time PCR
RNA was extracted from frozen quadriceps muscle using
Tri Reagent (Molecular Research Centre), according to the
manufacturer's protocol. Total RNA concentration was
determined spectrophotometrically at 260 nm. Prior to
reverse transcription (RT), all RNA samples were DNase-
treated (Promega), and first-strand cDNA was generated
from 1-μg RNA using AMV RT (Promega). Pre-designed
TaqMan Gene Expression Assays (Applied Biosystems)
were used containing specific primers and probes for the
genes of interest. Real-time PCR was performed using
Applied Biosystems 7500 detection system and PCRs were
performed using TaqMan Gene Expression Master Mix
(Applied Biosystems). To compensate for variations in
input RNA amounts and efficiency of reverse transcription,
GAPDH mRNA was quantified and all results were
normalised to these values. Fluorescent emission data were
captured and mRNA levels were analysed using the CT
value [17].
2.4 Protein electrophoresis and western blotting
Protein was extracted from frozen quadriceps muscle
homogenised in ice-cold radio-immunoprecipitation assay
buffer containing Tris–HCl (50 mmol/L; pH 7.4), NaCl
(150 mmol/L), NP-40 (1%), sodium deoxycholate (0.5%)
and SDS (0.1%) and centrifuging at 13,000×g for 15 min at
4°C, to remove insoluble material. The protein concentra-
tion was determined by the Bradford method (Bio-Rad) and
equal amounts of protein were separated by SDS-PAGE and
transferred to polyvinylidene difluoride membranes. The
membranes were blocked for 2 h at room temperature in
Tris-buffered saline containing Tris–HCl (20 mM; pH 7.6)
NaCl (137 mM) and Tween 20 (0.1%) with 5% BSA and
probed with primary antibodies for either NOX2
(gp91phox), p40phox, p67phox or GAPDH (1:200; Santa Cruz
Biotechnology) overnight at 4°C. Antibody binding was
detected using horseradish peroxidase-conjugated secondary
antibody (1:50,000; Santa Cruz Biotechnology). The protein
bands were detected by SuperSignal West Dura chemilumi-
nescence reagents (Thermo Scientific). The LAS 4000
Imaging System (Fujifilm Life Science, USA) was used to
visualize protein bands, and densitometry was performed with
MultiGauge software (Fujifilm Life Science, USA). To
compensate for variation in protein loading, the relative
density of immunoreactive bands were normalised to the
density of the corresponding bands for GAPDH.
2.5 Antioxidant enzyme activity and hydrogen
peroxide assays
Spectrophotometric assay kits were used to measure SOD
(Cayman-706002), catalase (Cayman-707002) and GPx
(Cayman- 703102) activity and hydrogen peroxide (Cayman-
600050) levels, in muscle homogenates. Frozen muscle pieces
(100 mg) were placed in ice-cold HEPES buffer (20 mM)
containing EGTA (1 mM), mannitol (210 mM) and sucrose
(70mM) and adjusted to a pH of 7.2 (10ml/g). Muscle aliquots
were homogenised in buffer, using a glass on glass homoge-
niser, and centrifuged at 1,500×g for 5 min at 4°C to remove
insoluble connective tissue. For the detection of SOD1 and
SOD2, cytosolic and mitochondrial fractions were separated.
The supernatant was centrifuged at 10,000×g for 5 min
at 4°C, and the resulting supernatant, containing the
cytosolic fraction, was collected for SOD1 enzyme
analysis. The remaining pellet containing the mitochon-
drial fraction was resuspended and homogenised in ice-
cold HEPES buffer (20 mM) for SOD2 enzyme analysis.
SOD1 and SOD2 activity was measured in cytosolic and
mitochondrial muscle fractions, respectively. The amount
of enzyme activity and hydrogen peroxide levels were
calculated and standardised for protein using the Bradford
method (Bio-Rad).
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2.6 Statistical analysis
Statistical analysis was performed using SPSS statisti-
cal package (version 15.0). Results are expressed as
mean±SEM. Differences were determined by one-way
ANOVA with Tukey HSD as posthoc to determine
significant differences between groups, and results were
considered statistically significant if p values were equal
to or <0.05.
3 Results
3.1 Establishment of murine model of cancer and cancer
cachexia
Female BALB/c nu/nu mice were implanted with the
MAC13 cell line (n=12) that had previously developed a
tumour in the same mouse model at approximately 9–
12 days post implantation (n=3) and where the animal did
not lose weight. Another group of female BALB/c nu/nu
mice were implanted with the MAC16 cell line (n=16) that
had previously developed a tumour in the same mouse
model at approximately 9–12 days post implantation (n=4)
and lost approximately 15–25% of their original body
weight were used in this study. Mouse body weight and
skeletal muscle weights were recorded at tissue collection
and evaluated as a measure of body mass and skeletal
muscle cachexia for all mice. Body weight and quadricep
weights were significantly less in cachectic (MAC16
tumour-bearing mice) when compared to mice with cancer
alone (bearing MAC13 tumours) (p<0.001; p=0.003,
Table 1). To account for any differences in calorie intake
between the groups, food intake was recorded throughout
the course of the study and showed no differences between
cachectic and cancer mice (Table 1).
3.2 O2
− levels in skeletal muscle of cancer and cancer
cachectic mice
O2
− levels were measured by histological DHE fluores-
cence in skeletal muscle sections from mice with cancer
and cachexia. Skeletal muscle O2
− levels were significantly
higher in cachectic mice (9.36±2.67 AU) when com-
pared to mice with cancer (6.47±0.77 AU) alone (p=
0.001, Fig. 1).
3.3 mRNA expression of pro-oxidant and antioxidant
enzymes in skeletal muscle of cancer and cancer
cachectic mice
The mRNA level of the NOX2 and NOX4 enzyme systems
previously shown to express in skeletal muscle to generate
O2
− were measured in mice with cancer and cancer
cachexia. The mRNA of the regulatory and catalytic
NOX2 enzyme subunits NOX2, p40phox and p67phox were
lower in the skeletal muscle of cachectic mice when
compared to mice with cancer alone (p=0.031; p<0.001;
p=0.002, Table 2). However, the mRNA expression of the
additional NOX enzyme subunits, NOX4, p22phox and
p47phox and Rac1 were similar in skeletal muscle from mice
bearing with cancer and cancer cachexia (Table 2). The
mRNA level of SOD antioxidant enzymes responsible for
the dismutation of O2
− were measured in mice with cancer
and cancer cachexia. The mRNA level of the SOD1 and
SOD2 were significantly lower in the skeletal muscle from
cachectic mice when compared to mice with cancer alone
(p=0.007; p<0.001, Table 2). Similarly, the mRNA level of
the H2O2 scavenging antioxidant enzyme GPx was lower in
skeletal muscle from cachectic mice compared to mice with
Table 1 Mean body weight, quadriceps weight and food intake of
mice with cancer and cancer cachexia
Weight Cancer Cachexia
Body weight (g) 22.3±0.3 17.1±0.3*
Quadriceps (mg) 117.0±4.2 90.1±2.1*
Food intake (g) 3.6±0.3 3.6±0.5
The values represent the mean±SEM
*P<0.003, statistically significant differences
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Fig. 1 O2
− levels in the skeletal muscle of mice with cancer and
cancer cachexia. The values represent the mean±SEM. Statistically
significant difference *P=0.001. a O2
− levels detected by dihydroe-
thidium (DHE) fluorescence expressed as arbitrary units of fluores-
cence . The values represent the mean±SEM. Statistically significant
difference *P=0.001. b Histological DHE fluorescence in the skeletal
muscle of mice with cancer and cancer cachexia
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cancer alone (p<0.001, Table 2). However, the antioxidant
enzymes SOD3 and catalase had similar mRNA levels in
both groups (Table 2).
3.4 Protein levels of NOX2 enzyme subunits in skeletal
muscle of cancer and cancer cachectic mice
Changes in the mRNA levels of the key NOX2 enzyme
subunits—NOX2, p40phox and p67phox—lead to further
analysis of protein expression. The protein expression of
the regulatory and catalytic NOX2 enzyme subunits
NOX2 and p40phox were lower in cachectic mice when
compared to mice with cancer alone (p=0.021; p<0.012,
Fig. 2). However, the protein expression of p67phox was
similar in skeletal muscle from mice in both groups
(Fig. 2).
3.5 Antioxidant enzyme activity and hydrogen peroxide
levels in skeletal muscle of cancer and cancer cachectic
mice
To validate changes in mRNA and protein levels, SOD1,
SOD2, catalase and GPx activity levels were measured in
skeletal muscle of mice with cancer and cancer cachexia.
SOD1 and GPx activities were significantly lower in
skeletal muscle from cachectic mice (SOD1 9.9±0.9 U/mg
protein, GPx 0.74±0.22 mmol/min/mg protein) when com-
pared to mice with cancer alone (SOD1 11.2±0.8 U/mg
protein, GPx 1.48±0.08 mmol/min/mg protein) (p<0.003,
Table 3). However, levels of SOD2 and catalase activity were
similar in both groups of (Table 3). H2O2 levels were similar
in skeletal muscle from cachectic mice and mice with cancer
alone (Table 3).
Table 2 Gene expression in skeletal muscle of mice with cancer and
cancer cachexia
Cancer Cachexia
Gene expression (AU)
NOX2 11.8±2.3 5.0±1.1*
p22phox 88.7±2.9 75.5±10.5
p40phox 21.4±2.8 7.9±1.6*
p47phox 5.7±1.2 7.3±1.4
p67phox 367±92.7 15.6±3.3*
NOX4 4.3±0.6 8.5±2.7
Rac1 3.6±1.1 7.5±1.6
SOD1 350±36.5 120±37.8*
SOD2 122±8.0 59.4±5.4*
SOD3 2.6±0.3 1.8±0.3
Gpx 23.5±2.3 12.8±1.2*
Catalase 49.3±7.3 43.2±5.6
The values represent the mean±SEM
*P<0.003, statistically significant differences
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Fig. 2 Protein expression levels of NOX2 enzyme subunits in the
skeletal muscle of mice with cancer and cancer cachexia. The
values represent the mean±SEM. Statistically significant differences
*P<0.05. a NOX2, b p40phox, c p67pho
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4 Discussion
Levels of O2
− were increased in cancer-induced skeletal
muscle cachexia. Evidence of this was found with increased
levels of O2
− detected by DHE fluorescence in the skeletal
muscle of cachectic mice, when compared to non-cachectic
mice. However, the NOX enzyme systems do not appear to
be the source of increased O2
− in cancer-induced skeletal
muscle cachexia. In fact, we observed a decrease in the
expression of the NOX2 enzyme subunits, NOX2, p40phox
and p67phox in cachectic skeletal muscle. Although this
study would imply an additional source of O2
− production
in cancer-induced skeletal muscle cachexia, what may be of
greater importance is the decrease in antioxidant enzyme
function, primarily responsible for O2
− dismutation. While
this study may be indicative of a lack of compensation by
SOD1 and GPx, it may give evidence for their depression, in
response to cancer induction and lack of dismutation of even
normal cellular O2
− production. The decrease in antioxidant
gene expression and activity that function as part of the
cellular defence system, for the elimination of O2
− and H2O2,
may indicate antioxidant dysfunction in cachectic skeletal
muscle, rather than an increase in ROS production.
Cancer induces changes in skeletal muscle that lead to an
imbalance in protein synthesis and degradation, resulting in
muscle protein loss and function [1]. Interestingly, not all
cancer patients develop this secondary condition, and it is
this phenomena that has made the development of cancer
cachexia relatively undefined [1, 2]. In order to investigate
this complex condition, we investigated a model that
utilises two similar MAC models, only one of which
induces the secondary muscle wasting condition of cancer
cachexia. The significant decline in body weight (15–25%)
and skeletal muscle mass that was observed in mice bearing
the MAC16 tumour, demonstrated the development of
cancer-induced skeletal muscle cachexia. While the
MAC16 cancer cachectic model is well-established in NMRI
mice [4], this study mimics the cachectic condition in
MAC16 tumour-bearing nude mice. This model of cancer
and cancer cachexia establishes a direct comparison between
a cancer control and cancer cachectic mouse model.
Contrasting studies have implicated the importance of calorie
restriction in the development of cancer cachexia; however,
our study, like others [18], did not observe any change in
food intake from cachectic mice. This study therefore
suggests a more complex catabolic-mediated response to
protein degeneration, in the development of cancer cachexia.
The physical changes in skeletal muscle were mirrored
by significant cellular oxidative changes in response to
MAC16 induction and cachectic development. In particular,
the significant increase in O2
− levels observed in cachectic
skeletal muscle indicates that O2
− is implicated in the
cancer cachectic condition. Previous studies have proposed
a central mediating role for ROS in the development of
cancer cachexia [5, 18]; however, the source of ROS in this
process remains to be elucidated. The knowledge that the
NOX enzyme system functions primarily to produce O2
−
[19], recognises NOX-generated O2
− as more than a by-
product of cellular metabolism, but rather a product of a
regulated response to stimuli for a physiological purpose.
This function of NOX makes this enzyme system the
potential source of O2
−, vulnerable to changes associated
with the cancer condition and development of cachexia. To
our knowledge, this study is the first to investigate the
NOX enzymes in cancer cachectic skeletal muscle. Inter-
estingly, the NOX2 enzyme has consistently been shown to
increase in degenerative conditions [19]; however, this
study does not support an increase in the NOX2 enzyme in
cancer cachexia.
It is evident, however, from this study and others, that
the absence of a functioning antioxidant enzyme system to
dismutate O2
− is present in cancer cachectic skeletal muscle
[20]. Cellular oxidative stress has been implicated in
skeletal muscle wasting conditions with marked attenuation
following antioxidant induction [21]. Despite the increase
in O2
- in cachectic skeletal muscle that is indicative of a
need for SOD activity, we observed a depression in SOD1
activity levels. Furthermore, our SOD gene expression data
would appear to suggest that the inability for SOD to
compensate for the increase in O2
− is regulated at the gene
level. Alterations in this important protective system can
lead to oxidative imbalance, and induce critical changes to
cellular structure and function [20]. Antioxidant enzymes
are valuable indicators of ROS production as well as
changes in cellular redox signalling and evidence of cell
functionality [13]. The consequences of SOD antioxidant
enzyme modifications have been demonstrated in studies
investigating SOD knockout models. Muller et al. [22]
demonstrated an age-dependent loss of muscle mass in
mice lacking SOD1, as well as a significant decrease in
their average life span. Furthermore, Sun et al. [23]
investigated the effects of SOD1 and SOD2 overexpression
in Drosophila that demonstrated a decrease in cumulative
Table 3 Enzyme activity and H2O2 levels in skeletal muscle of mice
with cancer and cancer cachexia
Cancer Cachexia
SOD1 (U/mg protein) 23.3±0.8 17.8±0.9*
SOD2 (U/mg protein) 11.2±0.8 9.9±0.8
Catalase (mmol/min/mg protein) 4.1±0.4 3.5±0.2
GPx (mmol/min/mg protein) 1.48±0.08 0.74±0.22*
H2O2 (μM) 1.11±0.07 1.15±0.04
The values represent the mean±SEM
*P<0.003, statistically significant differences
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oxidative damage and increased metabolic potential, with
an increased life span by up to 37% and 75%, respectively.
These models demonstrate a crucial role for SOD1 shown
through its significant contribution to oxidative damage and
muscle degeneration.
It is also not surprising that with a decline in O2
−
dismutation by SOD, to convert O2
− to H2O2, the gene
expression and activity of the H2O2 scavenging antioxidant
enzyme GPx would also decrease. Consequently, these
important cellular systems would indeed contribute to
significant changes in redox-sensitive signalling pathways
in cancer cachexia. SOD, not only has a crucial role in
eliminating O2
− accumulation, but also plays an important
role in intracellular redox-sensitive signalling and regula-
tion of oxidative systems [13]. As ROS have been
described as important mediators of redox-sensitive intra-
cellular signalling, so too are the antioxidants that regulate
them. It is well-known that with the generation of
intracellular O2
−, SOD1 functions to dismute O2
− to H2O2
[14]. H2O2 in particular, has been shown to be involved in
numerous signalling cascades, and therefore, its cellular
regulation, via SOD, has the potential to influence a
number of important cellular pathways [24]. The changes
in SOD1 function would indeed have critical consequences
to cellular function that is most certainly redox-related.
A circulatory protein, PIF was first described as a
causative agent in cachexia when it was discovered in mice
expressing the MAC16 tumour [25]. As this glycoprotein
was initially discovered in the sera of mice bearing the
cachectic MAC16 tumour, but not in the sera of the mice
bearing the non-cachectic MAC13 tumours, it was regarded
as an important factor in the development of cancer
cachexia [25]. The accelerated loss of skeletal muscle
protein in cachexia has been attributed to Ub-proteasome
pathway activation [15, 26], and PIF has been shown to
induce this pathway of skeletal muscle atrophy [26].
Although the PIF/Ub pathway indeed plays an important
role in the development of cancer cachexia [15], a number
of additional mechanisms are most likely involved [27].
Preproteasomal mechanisms, mediators, receptor binding,
signalling pathways and activation of specific transcription
factors are all important considerations [3] and ROS have
been implicated in these cellular processes.
Collectively, the results of this study suggest influential
signalling involving O2
− and antioxidant enzymes in cancer
cachectic skeletal muscle. However, the signalling pathway
(s) leading to the decrease in the NOX2 subunits and
antioxidant enzyme expression, together with decreased
antioxidant enzyme activity in cachectic skeletal muscle
remains undefined. In response to ROS, cells activate the
expression of a number of genes via transcription factor
regulation, leading to modifications in the gene expression
of important proteins, including antioxidant enzymes [13]
and those involved in muscle protein synthesis and
regeneration [28]. Furthermore, it is possible to speculate
that the downregulation of the NOX2 enzyme system is a
compensatory response to O2
− accumulation, induced
primarily by SOD and GPx antioxidant system dysfunction
and is therefore a regulated response to O2
− build-up in the
cellular system. However, with the knowledge that ROS
can cause damage to cellular proteins [29], it is possible
that the decrease in the NOX2 enzyme subunits and
antioxidant enzymes is a result of protein oxidation. With
this in mind, it would be important to investigate these
oxidative systems and the oxidative status of cachectic
skeletal muscle during the progression of the disease.
5 Conclusion
It is evident from cachectic studies that show the presence
of oxidised proteins and attenuation following antioxidant
administration that ROS play an important role in the
development of cachexia. Although the exact mechanisms
are poorly defined, experimental research in the NOX
enzyme systems have indicated a number of important roles
for ROS, in addition to direct oxidative tissue damage, for
its involvement in redox-sensitive signalling pathways.
While studies have implicated the involvement of ROS in
the pathogenesis of cachexia and have suggested a role for
NOX, this study suggests that the increase in O2
− in
cachectic skeletal muscle is a result of antioxidant dysfunc-
tion. However, what remains unclear is whether this result
is a regulated response in the cellular system or an
important contributor to the changes observed in skeletal
muscle physiology. Furthermore, with the well-established
role for the Ub-proteasome pathway in cancer cachexia, the
increase in O2
− levels in our study provides evidence of a
signalling role for O2
− in this pathway of skeletal muscle
atrophy in cancer cachexia. While these results, along with
the additional findings of this study indeed demonstrate
complex changes in cachectic skeletal muscle, this multi-
factoral condition coupled with a multifunctional system,
further demonstrates the complexity of skeletal muscle
response(s) to cancer induction. It is therefore important to
understand further the role that these oxidative and
antioxidative systems play in the skeletal muscle system
and development of cancer cachexia.
Acknowledgements This research was supported by Deakin
University and Victoria University. Melanie Sullivan-Gunn was
the recipient of a Victoria University postgraduate scholarship.
The authors would like to thank the staff of the Deakin University
Building Lp Animal House for their help and support with the
animal study. The authors of this manuscript certify that they
comply with the ethical guidelines for authorship and publishing
in the Journal of Cachexia, Sarcopenia and Muscle [30].
J Cachexia Sarcopenia Muscle (2011) 2:181–188 187
Conflicts of interest The authors declare that they have no conflict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
References
1. Giordano A, Calvani M, Petillo O, Carteni M, Melone MR,
Peluso G. Skeletal muscle metabolism in physiology and in cancer
disease. J Cell Biochem. 2003;90:170–86.
2. Tijerina AJ. The biochemical basis of metabolism in cancer
cachexia. Dimens Crit Care Nurs. 2004;23:237–43.
3. Hasselgren PO, Wray C, Mammen J. Molecular regulation of
muscle cachexia: it may be more than the proteasome. Biochem
Biophys Res Commun. 2002;290:1–10.
4. Hussey HJ, Tisdale MJ. Effect of a cachectic factor on
carbohydrate metabolism and attenuation by eicosapentaenoic
acid. Br J Cancer. 1999;80:1231–5.
5. Barreiro E, de la Puente B, Busquets S, Lopez-Soriano FJ, Gea J,
Argiles JM. Both oxidative and nitrosative stress are associated
with muscle wasting in tumour-bearing rats. FEBS Lett.
2005;579:1646–52.
6. Eley HL, Tisdale MJ. Skeletal muscle atrophy, a link between
depression of protein synthesis and increase in degradation. J Biol
Chem. 2007;282:7087–97.
7. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G,
Lusso MR, et al. Antioxidant agents are effective in inducing
lymphocyte progression through cell cycle in advanced cancer
patients: assessment of the most important laboratory indexes of
cachexia and oxidative stress. J Mol Med. 2003;81:664–73.
8. Groemping Y, Rittinger K. Activation and assembly of the NADPH
oxidase: a structural perspective. Biochem J. 2005;386:401–16.
9. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by
TNF-alpha in differentiated skeletal muscle myotubes. Am J
Physiol Regul Integr Comp Physiol. 2000;279:R1165–70.
10. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of
gp91phox: cloning and tissue expression of Nox3, Nox4, and
Nox5. Gene. 2001;269:131–40.
11. Mansouri A, Muller FL, Liu Y, Ng R, Faulkner J, Hamilton M, et
al. Alterations in mitochondrial function, hydrogen peroxide
release and oxidative damage in mouse hind-limb skeletal muscle
during aging. Mech Ageing Dev. 2006;127:298–306.
12. Hidalgo C, Sanchez G, Barrientos G, Aracena-Parks P. A
transverse tubule NADPH oxidase activity stimulates calcium
release from isolated triads via ryanodine receptor type 1 S -
glutathionylation. J Biol Chem. 2006;281:26473–82.
13. Ji LL. Antioxidant signaling in skeletal muscle: a brief review.
Exp Gerontol. 2007;42:582–93.
14. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene
family: a comparison of the CuZn-SOD (SOD1), Mn-SOD
(SOD2), and EC-SOD (SOD3) gene structures, evolution, and
expression. Free Radic Biol Med. 2002;33:337–49.
15. Smith HJ, Tisdale MJ. Signal transduction pathways involved in
proteolysis-inducing factor induced proteasome expression in
murine myotubes. Br J Cancer. 2003;89:1783–8.
16. Russell ST, Eley H, Tisdale MJ. Role of reactive oxygen
species in protein degradation in murine myotubes induced by
proteolysis-inducing factor and angiotensin II. Cell Signal.
2007;19:1797–806.
17. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ,
Reed MW. Quantitative reverse transcription-polymerase chain
reaction to study mRNA decay: comparison of endpoint and
real-time methods. Anal Biochem. 2000;285:194–204.
18. Baracos VE. Regulation of skeletal-muscle-protein turnover in
cancer-associated cachexia. Nutrition. 2000;16:1015–8.
19. Bedard K, Krause KH. The NOX family of ROS-generating
NADPH oxidases: physiology and pathophysiology. Physiol Rev.
2007;87:245–313.
20. McCord JM, Edeas MA. SOD, oxidative stress and human
pathologies: a brief history and a future vision. Biomed Pharmacother.
2005;59:139–42.
21. Hussey HJ, Bibby MC, Tisdale MJ. Novel anti-tumour activity of
2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504)
against established murine adenocarcinomas (MAC). Br J Cancer.
1996;73:1187–92.
22. Muller FL, Song W, Liu Y, Chaudhuri A, Pieke-Dahl S, Strong R,
et al. Absence of CuZn superoxide dismutase leads to elevated
oxidative stress and acceleration of age-dependent skeletal muscle
atrophy. Free Radic Biol Med. 2006;40:1993–2004.
23. Sun J, Folk D, Bradley TJ, Tower J. Induced overexpression of
mitochondrial Mn-superoxide dismutase extends the life span of
adult Drosophila melanogaster. Genetics. 2002;161:661–72.
24. True AL, Rahman A, Malik AB. Activation of NF-kappaB
induced by H(2)O(2) and TNF-alpha and its effects on ICAM-1
expression in endothelial cells. Am J Physiol Lung Cell Mol
Physiol. 2000;279:L302–11.
25. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M.
Characterization of a cancer cachectic factor. Nature. 1996;379:739–
42.
26. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et
al. Multiple types of skeletal muscle atrophy involve a common
program of changes in gene expression. FASEB J. 2004;18:39–51.
27. Tisdale MJ. Tumor-host interactions. J Cell Biochem. 2004;93:871–
7.
28. Klaunig JE, Kamendulis LM. The role of oxidative stress in
carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–67.
29. Mecocci P, Fano G, Fulle S, MacGarvey U, Shinobu L, Polidori
MC, et al. Age-dependent increases in oxidative damage to DNA,
lipids, and proteins in human skeletal muscle. Free Radic Biol
Med. 1999;26:303–8.
30. von Haehling S, Morley J, Coats A, SD A. Ethical guidelines for
authorship and publishing in the Journal of Cachexia, Sarcopenia
and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.
188 J Cachexia Sarcopenia Muscle (2011) 2:181–188
